Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 5, 2019

Primary Completion Date

January 10, 2024

Study Completion Date

January 31, 2026

Conditions
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab

Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months

Trial Locations (12)

Unknown

Aberdeen Royal Infirmary (NHS Grampian), Aberdeen

Bristol Haematology and Oncology Centre (University Hospital Bristol NHS Foundation Trust), Bristol

Western General Hospital (NHS Lothian), Edinburgh

East Suffolk and North Essex NHS Foundation Trust, Ipswich

Guy's and St Thomas' NHS Foundation Trust, London

University College London Hospital, London

The Christie NHS Foundation Trust, Manchester

The Clatterbridge Cancer Centre NHS Foundation Trust, Metropolitan Borough of Wirral

East and North Hertfordshire NHS Trust, Northwood

Queens Hospital (Barking, Havering and Redbridge University Hospitals NHS Trust), Romford

Musgrove Park Hospital (Somerset NHS Foundation Trust), Taunton

Royal Cornwall Hospital Trust, Truro

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University College, London

OTHER